Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Markus Muschen, MD, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentLaboratory Medicine
    Address513 Parnassus Ave, Med Sci
    San Francisco CA 94143
    Phone415-502-0388
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Institute of Genetics, University of Cologne, Cologne, GermanyPhDDepartment of Immunology2003
      University Medical Center Cologne, Cologne, GermanyClinical trainingDepartment of Haematology-Oncology2001
      University Medical Center Düsseldorf, GermanyPhysician-in-trainingDepartment of Medicine2000
      University of Dusseldorf, GermanyM.D.University Medical Center Düsseldorf2000
      University of Paris V, René Descartes, FranceMedical studentInstitut Pasteur1997
      University of Nantes, Nantes, FranceMedical studentINSERM Unité 437, Transplantation Immunology1995
      Collapse Awards and Honors
      National Cancer Institute2016NCI Outstanding Investigator Award
      Wellcome Trust2013Wellcome Trust Senior Investigator Award
      The Institute of Cancer Research, London, UK2012Haddow Professorship
      Leukemia and Lymphoma Society2010Scholar Award
      German Association of Hematology and Oncology2006Leukemia Research Award
      German Association for Immunology2004Fritz-Melchers Award
      University of Cologne2003Habilitation Thesis Award
      State of North-Rhine Westphalia2002Stem Cell Research Award
      German Science Foundation (DFG)2001Emmy-Noether Young Investigator Award
      Heinrich-Heine-Universitat Dusseldorf1999Doctoral Thesis Award

      Collapse Overview 
      Collapse Overview
      ACTIVE RESEARCH SUPPORT

      R01CA137060-A1 Müschen (PI) 04/01/2008 - 12/31/2012
      NCI/NIH
      “Pre-B cell receptor signaling in acute lymphoblastic leukemia”. The central goal of this project is to clarify the role of pre-B cell receptor signaling in acute lymphoblastic leukemia.

      R01CA139032 Müschen (PI) 04/01/2008 - 12/31/2012
      NCI/NIH
      “AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia”. The central goal is (1) to identify the regulatory mechanisms that lead to aberrant expression of AID and (2) to identify the consequences of aberrant AID-activity in leukemia cells.

      1R01CA157644 Müschen (PI) 04/01/2011-03/31/2016
      NIH/NCI
      ‘Infectious origins of childhood leukemia’. The central goal of this proposal is to experimentally test the ‘delayed infections hypothesis’ in the etiology of childhood ALL and to delineate mechanisms of genetic vulnerability of human pre-B cells in the context of infection.

      R21CA152497 Müschen (PI) 06/01/2010 - 05/31/2012
      NCI/NIH
      “Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia”. The central goals of this proposal are (1) to clarify the role of BCL6 in leukemia-initiation of Ph+ ALL and (2) To determine the frequency and phenotype of BCL6-dependent leukemia stem cells.

      TR2-01816 Müschen (PI) 10/01/2010-09/30/2013
      California Institute for Regenerative Medicine (CIRM)
      Early Translation Award. Development of a BCL6 small molecule inhibitor for targeted eradication of leukemia stem cells. The main goals of this project are (1) computer aided drug-design of BCL6 lateral groove inhibitors, (2) PK/PD assays and SAR studies of identified lead compound series and (3) pre-clinical validation.

      AACR 138564 Müschen (PI) 12/01/2009 - 11/30/2012
      AACR Stand Up To Cancer Innovation Award
      Stand Up To Cancer Innovation Award: Role of BCL6 in leukemia stem cell self-renewal. The main goal of this project is to study the role of BCL6 in the maintenance of leukemia-initiating cells in ALL.

      LLS 1497-11 Müschen (PI) 10/01/2010-09/30/2015
      The Leukemia and Lymphoma Society Scholar Award
      Leukemia and Lymphoma Society Scholar Award, will cover salary expenses related to NIH grant R01CA137060 ‘Pre-B cell receptor signaling in acute lymphoblastic leukemia’.

      LLS 6132-09 Müschen (PI) 10/01/2008-09/30/2012
      The Leukemia and Lymphoma Society
      Translational Research Grant ‘Targeting AID in BCR-ABL1-driven leukemia’. The main goal of this project is to study the role of AID in aberrant somatic hypermutation as a cause of genetic instability.

      LLS 6097-10 Müschen (PI) 07/01/2009-06/30/2013
      The Leukemia and Lymphoma Society
      Translational Research Grant ‘BCL6 in oncogene-induced senescence’. The main goal of this project is to study the role of BCL6 in oncogene-induced senescence in MYC-driven B cell lymphoma.

      LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015
      Leukemia and Lymphoma Society SCOR
      Project 2: Dual targeting of tyrosine kinase and feedback signaling in leukemia. Goals are identification of novel oncogenic tyrosine kinases and characterization of feedback mechanisms in response to tyrosine kinase inhibition. Brian J Druker, Portland, OR is the PI of the SCOR.

      LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015
      Leukemia and Lymphoma Society SCOR
      Core E: (1) Generate and make xenografted samples available to SCOR projects, (2) Generate a centralized multidimensional database which links flow cytometry data, cytogenetics, gene expression, SNP chip analysis and clinical information. Brian J Druker, Portland, OR is the PI of the SCOR.


      Collapse ORNG Applications 
      Collapse Awarded Grants
      Collapse Global Health
      Collapse Featured Publications

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekoffer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LaBoeuf N, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 Apr 11; 29(4):574-86. PMID: 27070704.
        View in: PubMed
      2. Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP. Inhibition of IRE1a-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016 Apr 5; 7(14):18736-49. PMID: 26934650.
        View in: PubMed
      3. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016 Apr; 22(4):379-87. PMID: 26974310.
        View in: PubMed
      4. Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28; 127(17):2131-43. PMID: 26864341.
        View in: PubMed
      5. Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016 May; 30(5):1155-65. PMID: 26847029.
        View in: PubMed
      6. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 Jun; 30(6):1246-54. PMID: 26847027.
        View in: PubMed
      7. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27. PMID: 26711339.
        View in: PubMed
      8. Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S. Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia. Leukemia. 2016 Jun; 30(6):1436-40. PMID: 26639180.
        View in: PubMed
      9. Greaves M, Müschen M. Infection and the Perils of B-cell Activation. Cancer Discov. 2015 Dec; 5(12):1244-6. PMID: 26637659.
        View in: PubMed
      10. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Nov 5; 126(19):2202-12. PMID: 26324703; PMCID: PMC4635116 [Available on 11/05/16].
      11. Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood. 2015 Oct 8; 126(15):1813-22. PMID: 26219304; PMCID: PMC4600018.
      12. Swaminathan S, Müschen M. Infectious origins of childhood leukemia. Oncotarget. 2015 Jul 10; 6(19):16798-9. PMID: 26196452; PMCID: PMC4627260.
      13. Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):114-28. PMID: 26073130; PMCID: PMC4565502.
      14. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015 Jul; 16(7):766-74. PMID: 25985233; PMCID: PMC4475638 [Available on 01/01/16].
      15. Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM. HSP90 inhibitors decrease AID levels and activity in mice and in human cells. Eur J Immunol. 2015 Aug; 45(8):2365-76. PMID: 25912253; PMCID: PMC4536124 [Available on 08/01/16].
      16. Müschen M. Ph+ ALL: drawing strength from a benign past. Blood. 2015 May 7; 125(19):2879-80. PMID: 25953975; PMCID: PMC4424411 [Available on 05/07/16].
      17. Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol. 2015; 8:39. PMID: 25895498; PMCID: PMC4408565.
      18. Müschen M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015 Jun 11; 125(24):3688-93. PMID: 25878119; PMCID: PMC4463734 [Available on 06/11/16].
      19. Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21; 521(7552):357-61. PMID: 25799995; PMCID: PMC4441554 [Available on 11/21/15].
      20. Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nat Commun. 2015; 6:6471. PMID: 25753524; PMCID: PMC4366523.
      21. Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Mark Ansel K, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 9; 27(3):409-25. PMID: 25759025; PMCID: PMC4618684 [Available on 03/09/16].
      22. Lu Z, Lieber MR, Tsai AG, Pardo CE, Müschen M, Kladde MP, Hsieh CL. Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin. Mol Cell Biol. 2015 Apr; 35(7):1209-22. PMID: 25624348; PMCID: PMC4355534.
      23. Buchner M, Swaminathan S, Chen Z, Müschen M. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. Immunol Rev. 2015 Jan; 263(1):192-209. PMID: 25510278.
        View in: PubMed
      24. Swaminathan S, Müschen M. Follicular lymphoma: too many reminders for a memory B cell. J Clin Invest. 2014 Dec; 124(12):5095-8. PMID: 25384212; PMCID: PMC4348960 [Available on 12/01/15].
      25. Fontanari Krause LM, Japp AS, Krause A, Mooster J, Chopra M, Müschen M, Bohlander SK. Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL. Sci Rep. 2014; 4:6565. PMID: 25298122; PMCID: PMC4190505.
      26. Buchner M, Müschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014 Jul; 21(4):341-9. PMID: 24811161; PMCID: PMC4136419.
      27. Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):E2219-28. PMID: 24821775; PMCID: PMC4040579.
      28. Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH, Klemm L, Müschen M, Chen CC. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget. 2014 Jan 15; 5(1):211-23. PMID: 24457556; PMCID: PMC3960202.
      29. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O'Meara S, Teague JW, Butler AP, Cazzaniga G, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014 Feb; 46(2):116-25. PMID: 24413735; PMCID: PMC3960636.
      30. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. PMID: 24346116; PMCID: PMC3975047.
      31. Swaminathan S, Duy C, Müschen M. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends Immunol. 2014 Mar; 35(3):131-7. PMID: 24332591; PMCID: PMC3943645.
      32. Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Müschen M, Meeker N, Trede N, Frazer JK, Zhou Y, Cheng C, Jeha S, Pui CH, Willman CL, Harvey RC, Hunger SP, Yang JJ, Barnette P, Mullighan CG, Miles RR, Schiffman JD. VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia. 2014 Jan; 28(1):216-20. PMID: 23881307; PMCID: PMC4043450.
      33. Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013 Aug; 19(8):1014-22. PMID: 23852341; PMCID: PMC3954721.
      34. Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 2013 Aug 15; 122(7):1293-304. PMID: 23836560; PMCID: PMC3744994.
      35. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 2014 Apr 24; 33(17):2169-78. PMID: 23728349; PMCID: PMC3994178.
      36. Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia. J Exp Med. 2013 Apr 8; 210(4):805-19. PMID: 23478187; PMCID: PMC3620349.
      37. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Shojaee S, Klemm L, Parameswaran R, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bönig H, Kim YM. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood. 2013 Mar 7; 121(10):1814-8. PMID: 23319569; PMCID: PMC3591800.
      38. Cui X, Lu Z, Kurosawa A, Klemm L, Bagshaw AT, Tsai AG, Gemmell N, Müschen M, Adachi N, Hsieh CL, Lieber MR. Both CpG methylation and activation-induced deaminase are required for the fragility of the human bcl-2 major breakpoint region: implications for the timing of the breaks in the t(14;18) translocation. Mol Cell Biol. 2013 Mar; 33(5):947-57. PMID: 23263985; PMCID: PMC3623081.
      39. Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 2013 Jan 3; 121(1):148-55. PMID: 23152540; PMCID: PMC3538327.
      40. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012 Nov 13; 22(5):656-67. PMID: 23153538; PMCID: PMC3500515.
      41. Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012 Nov; 2(11):1004-23. PMID: 23107779; PMCID: PMC3516186.
      42. Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, Soverini S, Pane F, Foà R, Baccarani M, Müschen M, Perini G, Martinelli G. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One. 2012; 7(7):e40934. PMID: 22848414; PMCID: PMC3405023.
      43. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Müschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood. 2012 Jun 14; 119(24):5621-31. PMID: 22490804; PMCID: PMC3382926.
      44. Jiang XX, Nguyen Q, Chou Y, Wang T, Nandakumar V, Yates P, Jones L, Wang L, Won H, Lee HR, Jung JU, Müschen M, Huang XF, Chen SY. Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity. 2011 Dec 23; 35(6):883-96. PMID: 22169041; PMCID: PMC4098839.
      45. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24; 208(11):2163-74. PMID: 21911423; PMCID: PMC3201200.
      46. Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011 Oct 13; 118(15):4174-8. PMID: 21856866; PMCID: PMC3204735.
      47. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011 Aug 25; 118(8):2191-9. PMID: 21715311; PMCID: PMC3162353.
      48. Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Müschen M, Wang D. American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation. Am J Blood Res. 2011; 1(1):106-9. PMID: 22432071; PMCID: PMC3301414.
      49. Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Muschen M, Wang D. Launching of american journal of blood research. Am J Blood Res. 2011; 1(1):i. PMID: 22432072; PMCID: PMC3301420.
      50. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011 May 19; 473(7347):384-8. PMID: 21593872; PMCID: PMC3597744.
      51. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011 May 15; 17(10):3219-32. PMID: 21474579; PMCID: PMC3096723.
      52. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal. 2011; 4(166):ra18. PMID: 21447799; PMCID: PMC4057100.
      53. Thai M, Ting PY, McLaughlin J, Cheng D, Müschen M, Witte ON, Colicelli J. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 2011 Feb; 25(2):290-300. PMID: 21102429; PMCID: PMC3049868.
      54. Gruber TA, Chang MS, Sposto R, Müschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 2010 Oct 1; 70(19):7411-20. PMID: 20876806; PMCID: PMC2948648.
      55. Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Müschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res. 2010 Nov 1; 70(21):8299-308. PMID: 20837665; PMCID: PMC3989903.
      56. Yun JP, Behan JW, Heisterkamp N, Butturini A, Klemm L, Ji L, Groffen J, Müschen M, Mittelman SD. Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models. Cancer Prev Res (Phila). 2010 Oct; 3(10):1259-64. PMID: 20823291; PMCID: PMC2955776.
      57. Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM, Ye BH, Müschen M. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010 Jun 7; 207(6):1209-21. PMID: 20498019; PMCID: PMC2882829.
      58. Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res. 2010 Jun 1; 70(11):4346-56. PMID: 20460528; PMCID: PMC2880197.
      59. Müschen M. Genetic relicts from the origin of ALL. Blood. 2010 Apr 29; 115(17):3424-5. PMID: 20430963.
        View in: PubMed
      60. Wang XM, Greiner TC, Bibikova M, Pike BL, Siegmund KD, Sinha UK, Müschen M, Jaeger EB, Weisenburger DD, Chan WC, Shibata D, Fan JB, Hacia JG. Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations. J Cell Biochem. 2010 Mar 1; 109(4):818-27. PMID: 20069569; PMCID: PMC3122883.
      61. Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 2010 Apr; 24(4):813-20. PMID: 20111071; PMCID: PMC3038787.
      62. Nahar R, Müschen M. Pre-B cell receptor signaling in acute lymphoblastic leukemia. Cell Cycle. 2009 Dec; 8(23):3874-7. PMID: 19901533; PMCID: PMC4047560.
      63. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood. 2010 Feb 4; 115(5):1049-53. PMID: 19965645; PMCID: PMC2817631.
      64. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009 Sep 8; 16(3):232-45. PMID: 19732723; PMCID: PMC2931825.
      65. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Müschen M. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009 Aug 3; 206(8):1739-53. PMID: 19620627; PMCID: PMC2722172.
      66. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008 Dec 12; 135(6):1130-42. PMID: 19070581; PMCID: PMC2642632.
      67. Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G, Vitale A, Chiaretti S, Müschen M, Foà R, Baccarani M, Martinelli G. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica. 2008 Dec; 93(12):1814-21. PMID: 18838475.
        View in: PubMed
      68. Melchior K, Weiss J, Zaehres H, Kim YM, Lutzko C, Roosta N, Hescheler J, Müschen M. The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biol Chem. 2008 Jul; 389(7):897-903. PMID: 18681827.
        View in: PubMed
      69. Müschen M. Highlight: self-renewal signaling in stem cells. Biol Chem. 2008 Jul; 389(7):787. PMID: 18681824.
        View in: PubMed
      70. Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer. 2007; 6:67. PMID: 17958915; PMCID: PMC2169263.
      71. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med. 2007 May 14; 204(5):1157-66. PMID: 17485517; PMCID: PMC2118573.
      72. Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity. 2007 Mar; 26(3):323-33. PMID: 17331747.
        View in: PubMed
      73. Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen NS, Greeve J, Parwaresch R. Immunoglobulin class-switch recombination occurs in mantle cell lymphomas. J Pathol. 2006 Jun; 209(2):250-7. PMID: 16508921.
        View in: PubMed
      74. Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells. Oncogene. 2006 Aug 24; 25(37):5180-6. PMID: 16636677.
        View in: PubMed
      75. Sprangers M, Feldhahn N, Herzog S, Hansmann ML, Reppel M, Hescheler J, Jumaa H, Siebert R, Müschen M. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells. Oncogene. 2006 Aug 17; 25(36):5056-62. PMID: 16568084.
        View in: PubMed
      76. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene. 2006 Feb 16; 25(7):1118-24. PMID: 16205638.
        View in: PubMed
      77. Feldhahn N, Río P, Soh BN, Liedtke S, Sprangers M, Klein F, Wernet P, Jumaa H, Hofmann WK, Hanenberg H, Rowley JD, Müschen M. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A. 2005 Sep 13; 102(37):13266-71. PMID: 16141323; PMCID: PMC1201599.
      78. Soh BN, Klein F, Feldhahn N, Müschen M. B-lymphoid or myeloid lineage identity of cell lines derived from chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet. 2005 Sep; 161(2):187-8. PMID: 16102593.
        View in: PubMed
      79. Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Müschen M. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med. 2005 Jun 6; 201(11):1837-52. PMID: 15939795; PMCID: PMC2213268.
      80. Klein F, Feldhahn N, Mooster JL, Sprangers M, Hofmann WK, Wernet P, Wartenberg M, Müschen M. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol. 2005 Jan 1; 174(1):367-75. PMID: 15611260.
        View in: PubMed
      81. Su YW, Herzog S, Lotz M, Feldhahn N, Müschen M, Jumaa H. The molecular requirements for LAT-mediated differentiation and the role of LAT in limiting pre-B cell expansion. Eur J Immunol. 2004 Dec; 34(12):3614-22. PMID: 15549729.
        View in: PubMed
      82. Klein F, Feldhahn N, Müschen M. Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells. Cell Cycle. 2004 Jul; 3(7):858-60. PMID: 15254401.
        View in: PubMed
      83. Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller HW, Zanjani E, Wernet P. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004 Jul 19; 200(2):123-35. PMID: 15263023; PMCID: PMC2212008.
      84. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, Wernet P, Siebert R, Müschen M. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004 Mar 1; 199(5):673-85. PMID: 14993251; PMCID: PMC2213306.
      85. Schuster VH, Müschen M. Epstein-Barr virus and the B cell: a secret romance. Trends Microbiol. 2003 Jun; 11(6):243-5. PMID: 12823936.
        View in: PubMed
      86. Klein F, Feldhahn N, Lee S, Wang H, Ciuffi F, von Elstermann M, Toribio ML, Sauer H, Wartenberg M, Barath VS, Krönke M, Wernet P, Rowley JD, Müschen M. T lymphoid differentiation in human bone marrow. Proc Natl Acad Sci U S A. 2003 May 27; 100(11):6747-52. PMID: 12738882; PMCID: PMC164518.
      87. Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J, Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003 Mar; 17(3):503-5. PMID: 12514119.
        View in: PubMed
      88. Müschen M, Lee S, Zhou G, Feldhahn N, Barath VS, Chen J, Moers C, Krönke M, Rowley JD, Wang SM. Molecular portraits of B cell lineage commitment. Proc Natl Acad Sci U S A. 2002 Jul 23; 99(15):10014-9. PMID: 12119411; PMCID: PMC126616.
      89. Müschen M, Rajewsky K, Krönke M, Küppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 2002 Feb; 23(2):75-80. PMID: 11929130.
        View in: PubMed
      90. Müschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. Int J Cancer. 2001 Apr 15; 92(2):309-10. PMID: 11291062.
        View in: PubMed
      91. Müschen M, Küppers R, Spieker T, Bräuninger A, Rajewsky K, Hansmann ML. Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes. Lab Invest. 2001 Mar; 81(3):289-95. PMID: 11310822.
        View in: PubMed
      92. Re D, Müschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, Diehl V, Wolf J. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001 Mar 1; 61(5):2080-4. PMID: 11280769.
        View in: PubMed
      93. Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann ML, Rajewsky K. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions. Blood. 2001 Feb 1; 97(3):818-21. PMID: 11157505.
        View in: PubMed
      94. Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med. 2000 Dec 18; 192(12):1833-40. PMID: 11120779; PMCID: PMC2213498.
      95. Müschen M, Re D, Bräuninger A, Wolf J, Hansmann ML, Diehl V, Küppers R, Rajewsky K. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. 2000 Oct 15; 60(20):5640-3. PMID: 11059754.
        View in: PubMed
      96. Müschen M, Beckmann MW. CD95 ligand expression as a criterion of malignant transformation in breast cancer. J Pathol. 2000 Aug; 191(4):468-70. PMID: 10918226.
        View in: PubMed
      97. Müschen M, Rajewsky K, Bräuninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Küppers R. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000 Jan 17; 191(2):387-94. PMID: 10637283; PMCID: PMC2195757.
      98. Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology. 2000 Jan; 99(1):69-77. PMID: 10651943; PMCID: PMC2327134.
      99. Müschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med (Berl). 2000; 78(6):312-25. PMID: 11001528.
        View in: PubMed
      100. Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D. CD95 ligand expression in dedifferentiated breast cancer. J Pathol. 1999 Nov; 189(3):378-86. PMID: 10547600.
        View in: PubMed
      101. Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol. 1999 Sep; 155(3):915-25. PMID: 10487849; PMCID: PMC1866905.
      102. Müschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Häussinger D. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Gastroenterology. 1999 Mar; 116(3):666-77. PMID: 10029626.
        View in: PubMed
      103. Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer. 1999 Feb 9; 80(4):564-72. PMID: 9935158.
        View in: PubMed
      104. Josien R, Douillard P, Guillot C, Müschen M, Anegon I, Chetritt J, Menoret S, Vignes C, Soulillou JP, Cuturi MC. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest. 1998 Dec 1; 102(11):1920-6. PMID: 9835616; PMCID: PMC509143.
      105. Müschen M, Warskulat U, Häussinger D, Moers C, Simon D, Even J. Deranged CD95 system in a case of Churg-Strauss vasculitis. Gastroenterology. 1998 Jun; 114(6):1351-2. PMID: 9618660.
        View in: PubMed
      106. Müschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology. 1998 Jan; 27(1):200-8. PMID: 9425938.
        View in: PubMed
      Back to TOP